Contact us Clinical Neurosciences (CNS) HOMEINNOVATIONS & THERAPEUTIC EXPERTISETHERAPEUTIC AREASCLINICAL NEUROSCIENCES (CNS) Exceptional medical expertise, with diverse backgrounds in academia and industry Endpoints in CNS trials can be influenced by many factors, especially those such as placebo effects, investigator biases and patient expectations. Continuous quality control is a critical element of medical and safety support. We know all endpoints must be protected to ensure that the patient’s contribution truly adds value. Parexel’s CNS practice encompasses four specialty areas (psychiatry, neuromodulation, neurodegeneration/neuroinflammation and rare neurological diseases), each with novel developments underway that hold great promise for treating disease. Conducting clinical trials for these conditions demands close collaboration with sites, especially for staff qualification and training, patient selection, eligibility decisions and instream monitoring of data quality and study conduct. We also work with sponsors collaboratively to consider novel designs, points of potential acceleration and areas of risk. Our CNS practice is distinguished by: Expert medical team (clinical neurologists, psychiatrists, doctoral-level psychologists, neuropsychologists and neuroscientists) with strong understanding of the scientific developments emerging in clinical neurosciences, experienced in complex CNS clinical trials in Early Phase to Phase IV in every region – North America, Latin America, Europe, Asia and Australia. Regulatory expertise in functional, cognitive and behavioral endpoints for use in CNS-related trials with different populations and indications. Expertise in study design including: pediatric and adult; common and rare disease; shorter-term studies to evaluate symptomatic treatments; longer-term studies to assess for disease modification; adaptive designs; the use of external control arms; and the use of real-world evidence. Experience incorporating state-of-the-art biomarkers and diagnostic adjudication approaches to ensure randomization of appropriate patients, and enhanced signal detection strategies to improve detection of drug/placebo differences. Seamless, end-to-end support of CNS drug development, from hospital-based First-in-Human studies to Proof of Concept, from Dose-Finding to Phase III confirmatory studies, and from long-term safety and post-marketing study commitments to indication expansion. Study feasibility experts who provide detailed critical data about regions, countries, sites, investigators, standards/quality of care and competing trials to provide accuracy in site selection, recruitment rates and timelines. Access to patient populations with neurological and psychiatric conditions. Dedicated Early Phase Clinical Research Units Substantial psychiatry and neurology clinical expertise, including capabilities such as continuous collection of cerebrospinal fluid for sampling, neuropsychological testing, and evaluation, and use of biomarkers and imaging for diagnosis and outcomes. Comprehensive neuropsychological evaluations across the spectrum of cognitive aging. Over the last 5 years, Parexel's CNS experience has included: Specialties At Parexel, Clinical Neurosciences is grouped among the four categories. Although there are commonalities among these, there are distinctions based on target types, therapeutic approaches, and study design. Psychiatry Psychiatry focuses on diseases characterized by alterations in mood, behavior, cognition and perceptions. Important diseases include schizophrenia, major depressive ... Expand Rare Neurological Diseases Of the approximately 7,000 rare diseases leading to significant morbidity, one in three has a neurologic component. Parexel combines our ... Expand Neuromodulation Neuromodulation focuses on neurological disorders associated with changes in neuronal excitation, inhibition and signalling. These include epilepsy, pain, ... Expand Neurodegeneration/ Neuroinflammation Illnesses characterized by the progressive loss of neurons, such as Alzheimer’s Disease and Parkinson’s ... Expand Epilepsy and Real World Data How Patients with Epilepsy Benefit from Real-World Data Read now Multiple Sclerosis Patient Talks About Decentralized Clinical Trials Watch now We are always available for a conversation. Select Country Afghanistan Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Colombia Comoros Congo Costa Rica Croatia (Hrvatska) Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Isle of Man Indonesia Iran Iraq Ireland Israel Italy Ivory Coast Jersey Jamaica Japan Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kosovo Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Northern Mariana Islands Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka St. Helena St. Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States minor outlying islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands (U.S.) Wallis and Futuna Islands Yemen Zambia Zimbabwe CORPORATE LINKS About Us News Events Careers Education Investigators My Preferences Global Locations SOLUTIONS Parexel Biotech Clinical Development Consulting Medical Affairs Real-World Evidence FSP STUDIES & VOLUNTEERS About Trials Participate in a Trial GLOBAL STUDY LOCATIONS Baltimore, US Los Angeles, US London, UK Berlin, DE 275 Grove St., Suite 101C, Newton, MA 02466 +1 617 454 9300 2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713 +1 919 544 3170 © 2000-2021. Parexel International Corporation. All Rights Reserved. Privacy Policy Terms of Service Modern Slavery Statement Act By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies